Literature DB >> 16581733

Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?

R F Miller1, M Shahmanesh, M D Talbot, M J Wiselka, P J Shaw, C Bacon, C M Robertson.   

Abstract

A 36 year old man presented with weight loss, cough, fever, and exertional dyspnoea shortly after a diagnosis of HIV infection. Symptoms and initial radiological abnormalities worsened after highly active antiretroviral therapy was started. An eventual diagnosis was established but multiple problems occurred throughout the treatment period. Differentiation between immune reconstitution inflammatory syndrome and an infective cause was problematic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581733      PMCID: PMC2564679          DOI: 10.1136/sti.2005.019323

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  6 in total

1.  Pyrexia of undetermined origin in the era of HAART.

Authors:  W Whitely; A Tariq; B Peters; G Kocjan; R F Miller
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

2.  Diagnostic utility of bone marrow sampling in HIV-infected patients since the advent of highly active antiretroviral therapy.

Authors:  M J Llewelyn; M Noursedeghi; A Dogan; S G Edwards; R F Miller
Journal:  Int J STD AIDS       Date:  2005-10       Impact factor: 1.359

3.  Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count.

Authors:  Keertan Dheda; Ajit Lalvani; Robert F Miller; Geoff Scott; Helen Booth; Margaret A Johnson; Alimuddin Zumla; Graham Aw Rook
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

Review 4.  Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.

Authors:  Stephen D Lawn; Linda-Gail Bekker; Robert F Miller
Journal:  Lancet Infect Dis       Date:  2005-06       Impact factor: 25.071

5.  BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.

Authors:  A L Pozniak; R F Miller; M C I Lipman; A R Freedman; L P Ormerod; M A Johnson; S Collins; S B Lucas
Journal:  HIV Med       Date:  2005-07       Impact factor: 3.180

6.  Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy.

Authors:  S J Buckingham; L J Haddow; P J Shaw; R F Miller
Journal:  Clin Radiol       Date:  2004-06       Impact factor: 2.350

  6 in total
  1 in total

1.  Development of a culturally appropriate health-related quality of life measure for human immunodeficiency virus-infected children in Thailand.

Authors:  Warunee Punpanich; Ron D Hays; Roger Detels; Kulkanya Chokephaibulkit; Umaporn Chantbuddhiwet; Pimsiri Leowsrisook; Wasana Prasitsuebsai
Journal:  J Paediatr Child Health       Date:  2010-10-26       Impact factor: 1.954

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.